Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization
Vox Sanguinis · 2026-11-09
DOI: 10.1111/vox.70414 ↗Abstract
Abstract Background and Objectives Immunoglobulin M (IgM) is a promising therapeutic agent. However, its production is limited by high molecular weight, complex structure and poor stability. This study aimed to develop a novel manufacturing process for high‐purity, stable plasma‐derived IgM while improving plasma utilization. Materials and Methods The flow‐through fraction from first‐step anion‐exchange chromatography (Step 1 AEX) in an intravenous immunoglobulin manufacturing process was used as the starting material. Second‐step AEX (Step 2 AEX) and third‐step mixed‐mode chromatography (Step 3 MMC) were used to remove impurities, including prekallikrein activator (PKA), immunoglobulin G (IgG), immunoglobulin A (IgA) and α2‐macroglobulin. The elution conditions for Step 2 AEX were optimized to improve IgM recovery and purity. Four resins were evaluated for Step 3 MMC, and separation conditions were optimized to increase IgM purity and recovery. Finally, formulation studies were conducted to improve IgM stability. Results The optimized conditions were stepwise elution for Step 2 AEX (0.4 M followed by 1.0 M sodium acetate), Capto Core 400 resin for flow‐through‐mode Step 3 MMC and loading at pH 7.8, conductivity 15.0 mS/cm and protein concentration 1.0% ( w / v ). Key impurities IgA and PKA were reduced to 0.184 ± 0.011 mg/mL and below the limit of detection (90%). By optimizing plasma utilization, this process represents a promising platform for next‐generation immunoglobulin therapies.
EUVIMED